Clinical study on the treatment of 38 cases of decompensation liver cirrhosis by lamivudine

Objective To observe the therapeutic effect of lamivudine on decompensation liver cirrhosis in hepatitis patients.Methods Thirty-eight and 35 liver cirrhosis patients were randomly divided into treatment and control group respectively,the treatment group patients had taken lamivudine besides liver protective treatment, control group patients only received lives protective treatment.Results In 38 patients of treatment group,after they had taken lamivudine for 1-5 years, their Child-Pugh grade scores decreased, there was significant difference compared with that of control group (P0.05); the negative transformation rate of HBV DNA and HBeAg was 92.11% and 22.73% respectively; in control group,the negative transformation rate of HBV DNA and HBeAg was 11.43% and 5.00% respectively, there was significant difference between two groups(P0.05). The mortality between 1～5 years in treatment and control group was 5.26% and 22.86% respectively, there was obvious difference between two groups (P0.05).Conclusion Lamivudine may supperss the replication of HBV, thus it can control and partly reverse the development of decompensation liver cirrhosis, it is safe as well.